Cantourage Group SE
5.44
EUR
+0.30
(+5.84%)
ISIN
DE000A3DSV01
Return %
Stock
S&P 500
1Y
69.47
14.20
3Y
-37.69
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Philip Schetter
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- Berlin Germany
- IPO Date
- Oct 11, 2022
- Website
- cantourage.com
- Similar Companies
- Business
- Cantourage Group SE is a Germany-based medical cannabis company and pharmaceutical platform provider engaged in the processing, importing, and commercial distribution of certified medical cannabis products, active pharmaceutical ingredients, and cannabis-based medicines. Founded in 2019 and headquartered in Berlin, Germany, the company operates across key European healthcare markets, primarily Germany and the United Kingdom, while sourcing raw materials from a global network of licensed cultivators across North America, South America, Africa, and Australasia. The company operates through three principal business segments: Medical Cannabis Products, Processing and Platform Services, and Healthcare and Clinical Services. Its comprehensive product and service portfolio includes: dried medical cannabis flowers across multiple therapeutic strains and chemotypes; full-spectrum cannabis extracts, oral solutions, and standardized cannabinoid oils; dronabinol active pharmaceutical ingredients and finished formulations for extemporaneous pharmacy compounding; customized pharmaceutical packaging, sterilization, and labeling compliant with European Good Manufacturing Practice (EU-GMP) standards; gentle, non-irradiated microbial treatment and pharmaceutical processing services; regulatory compliance, EU-GMP certification facilitation, and European market access advisory for international cultivators via its Fast Track Access platform; wholesale logistics, temperature-controlled warehousing, and fulfillment distribution to licensed pharmacies, pharmaceutical wholesalers, and hospital networks; and specialized clinical and telemedicine consultation services provided to qualifying patients through its United Kingdom subsidiary, Cantourage Clinic. In recent corporate and operational developments, Cantourage Group SE has substantially accelerated its commercial growth and expanded its market footprint in response to favorable regulatory shifts in European markets, particularly following the reclassification of medical cannabis under Germany's Cannabis Act. The company has broadened its product catalog by securing new strategic supply alliances and launching exclusive dried flower cultivars and extract formulations in partnership with top-tier cultivators from Canada, Colombia, and South Africa. To accommodate surging prescription demand across European pharmacies, Cantourage expanded its processing and storage capacities at its central Berlin facility. Additionally, the company strengthened its presence in the United Kingdom through strategic telemedicine enhancements and patient service expansions at the Cantourage Clinic, while continuing to onboard international pharmaceutical partners onto its end-to-end import and distribution infrastructure.